Sagimet Biosciences Inc. Series A Common Stock (SGMT)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with business quality and predictability. Sagimet is a 16-employee clinical-stage biopharmaceutical company developing FASN inhibitors, led by Denifanstat. There is no meaningful revenue: in fiscal 2023, the year ended 2023-12-31, revenue was $2.0M, and filed figures show no revenue for later periods. Losses are large and generally worsening: net income was -$27.9M in fiscal 2023 (year ended 2023-12-31), -$45.6M in fiscal 2024 (year ended 2024-12-31), and -$51.0M in fiscal 2025 (year ended 2025-12-31). In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was -$14.0M, versus -$10.4M in fiscal Q2 2025, the quarter ended 2025-06-30. That is not a compounding earnings machine; it is a cash-burning research operation. Free cash flow is -$41.7M over the trailing twelve months, a -9.8% FCF yield on the $423.9M market cap as calculated by FairStock. The balance sheet has low debt—D/E 0.01—and Altman Z-score 34.07, so near-term solvency may not be the immediate issue, but Piotroski F-score 1/9 confirms weak fundamental momentum. At the 2026-10-13 close of $7.98, FairStock shows P/B 1.92, ROE -24.37%, ROCE -16.41%, and P/E -6.33. A negative P/E and no revenue growth figure mean Graham's earnings-based valuation cannot support a margin of safety. The Lynch category is none, because of losses in each of the last four years. The upside rests on clinical and regulatory success, not on current business economics. I see a speculative drug-development story, not a proven moat or a bargain in the Graham sense.

In plain English: Sagimet is a small healthcare company testing a once-daily pill for liver disease, acne, and some cancers. It does not report meaningful product revenue and is losing money, including a $51.0 million loss in fiscal 2025, the year ended 2025-12-31. At $7.98 on 2026-10-13, the stock is mainly a bet on future trial results, and because there are no profits to judge it by, the price looks neither clearly cheap nor clearly expensive based on the figures given.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer